

## Efungumab

|           |   |
|-----------|---|
| Cat. No.: | HY-P9962  |
| CAS No.:  | 762260-74-2   |
| Target:   | Fungal  |
| Pathway:  | Anti-infection  |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                    |  |               |   |         |                           |                 |                                  |         |  |
|--------------------|--|---------------|---|---------|---------------------------|-----------------|----------------------------------|---------|--|
| <b>Description</b> | Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC) <sup>[1]</sup> .   |               |   |         |                           |                 |                                  |         |  |
| <b>In Vivo</b>     | <p>Efungumab (2 mg/kg, i.p., daily for 3 days) significantly decreases mean organ colony counts and increases negative liver biopsies for many of the isolates in CD1 mice models of disseminated <i>c. albicans</i> disease<sup>[2]</sup>.<br/>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>CD1 mice models of disseminated <i>c. albicans</i> disease<sup>[2]</sup></td></tr><tr><td>Dosage:</td><td>2 mg/kg, daily for 3 days</td></tr><tr><td>Administration:</td><td>Intraperitoneal injection (i.p.)</td></tr><tr><td>Result:</td><td>Decreased mean organ colony counts and increased negative liver biopsies for many of the isolates.</td></tr></table> | Animal Model: | CD1 mice models of disseminated <i>c. albicans</i> disease <sup>[2]</sup> | Dosage: | 2 mg/kg, daily for 3 days | Administration: | Intraperitoneal injection (i.p.) | Result: | Decreased mean organ colony counts and increased negative liver biopsies for many of the isolates. |
| Animal Model:      | CD1 mice models of disseminated <i>c. albicans</i> disease <sup>[2]</sup>  |               |   |         |                           |                 |                                  |         |  |
| Dosage:            | 2 mg/kg, daily for 3 days  |               |   |         |                           |                 |                                  |         |  |
| Administration:    | Intraperitoneal injection (i.p.)   |               |   |         |                           |                 |                                  |         |  |
| Result:            | Decreased mean organ colony counts and increased negative liver biopsies for many of the isolates.   |               |   |         |                           |                 |                                  |         |  |

### REFERENCES

[1]. Karwa R, et al. Efungumab: a novel agent in the treatment of invasive candidiasis. *Ann Pharmacother*. 2009 Nov;43(11):1818-23.

[2]. Cowen LE, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. *Proc Natl Acad Sci U S A*. 2009 Feb 24;106(8):2818-23.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA